Aligos Therapeutics, Inc. (ALGS)
5.34
+0.03
(+0.56%)
USD |
NASDAQ |
Oct 09, 16:00
5.32
-0.02
(-0.37%)
After-Hours: 20:00
Aligos Therapeutics EPS Diluted (Quarterly) : -0.1442 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1442 |
| March 31, 2026 | -2.215 |
| December 31, 2025 | -1.915 |
| September 30, 2025 | -3.041 |
| June 30, 2025 | -1.532 |
| March 31, 2025 | -2.113 |
| December 31, 2024 | -13.08 |
| September 30, 2024 | -3.070 |
| June 30, 2024 | 0.8078 |
| March 31, 2024 | -5.582 |
| December 31, 2023 | -5.502 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| Anika Therapeutics, Inc. | 0.2412 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
| Imunon, Inc. | -0.5412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.504M |
| Revenue (Quarterly) | 27.78M |
| Total Expenses (Quarterly) | 29.28M |
| Enterprise Value | 6.386M |
| Gross Profit Margin (Quarterly) | 99.08% |
| Profit Margin (Quarterly) | -5.41% |
| Earnings Yield | -137.0% |
| Normalized Earnings Yield | -141.22 |